

# **Building materials**

Sector outlook

Thanks for your support in the **Asiamoney Brokers Poll**. Please click here for our voting matrix. CLSA



### Industry insights from Impack (IMPC IJ) and Asahimas (AMFG IJ)

Indonesia's building materials industry is starting to see signs of recovery this year, 1Q23 performance is improving, and companies in the space are still targeting double-digit revenue growth this year. Impack Pratama (N-R) and Asahimas (N-R) as market leaders in the roofing and flat glass industries, respectively, continue to be optimistic for this year targeting +17% and +11% sales growth after the strong performance last year. IMPC is currently trading at 40x 2024 consensus PE, while AMFG is trading at 5.9x trailing PE.

#### Signs of recovery

- □ Companies within Indonesia's building materials industry are still targeting double-digit growth this year, as signs of recovery starts to be seen in 1Q23 performance.
- Across companies, IMPC has the highest revenue growth target, with a margin profile that is one of the highest across peers.
- As of 1Q23, all companies generally saw an increase in revenue. In terms of earnings, IMPC has the highest net profit growth of +48% YoY.

#### **IMPC: Leader of roofing products**


- □ IMPC is a market leader in roofing products in Indonesia, having 90% and 70% market share in its two main products of PC (polycarbonate) and uPVC roofs.
- □ Sales of its main roofing products (79% of revenue) were strong in the past two years (+31% in both 2021 and 2022), and this continued in 1Q23 with +9% YoY.
- □ After raising prices significantly about +15% in 2021-2022 due to cost pressure from raw materials, IMPC is now able to enjoy thicker margins as costs started to normalise.

#### **AMFG: Resilient glass market**

- Robust performance was also felt by AMFG, the market leader in the flat glass industry, driven by both its auto glass and flat glass segments. 1Q23 revenue rose +7% YoY after growing by +26% in 2021 and +17% in 2022.
- □ Auto glass has been especially strong following the domestic car sales trend, and has been growing faster than flat glass in recent years.
- Nevertheless, flat glass remains AMFG's main revenue contributor (70%). Sales have remained resilient, partly supported by rising use of glass and mirrors amidst the shifting trend to smaller-sized houses in the property sector.

#### **Outlook from management**

- □ Management of both IMPC and AMFG remain positive on the outlook for this year, with IMPC targeting Rp3.3tn revenue (+17%) and Rp390bn net profit (+27%), and AMFG aiming to achieve Rp6.2tn revenue (+11%) and Rp550bn net profit (+26%).
- □ IMPC is currently trading at 50.6x 2023 and 40.1x 2024 consensus PE, while AMFG is trading at 5.9x trailing PE.



# Wirandi Ng

wirandi.ng@clsa.com +62 21 5088 7854

Jonathan Mardjuki

+62 21 5088 7815

7 July 2023

# Indonesia Materials

Impack Pratama	IMPC IJ
Rec	<b>N-R</b>
Market cap	US\$1.3bn
3M ADV	US\$0.9m
Price	Rp360
Asahimas	AMFG IJ
Rec	<b>N-R</b>
Market cap	US\$0.2bn
3M ADV	US\$0.1m
Price	Rp5,775

Prices as of 6 July market close.



www.clsa.com

CLSA and CL Securities Taiwan Co., Ltd. ("CLST") do and seek to do business with companies covered in its research reports. As such, investors should be aware that there may be conflicts of interest which could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decisions.
For important disclosures please refer to page 8.
Prepared for - W: wirandi.ng@clsa.com

Click to rate this research

U

Great

::


Solid

Meh

Signs of recovery in the building materials industry

# Signs of recovery

Indonesia's building materials industry is starting to see signs of recovery this year, as noted in our previous report 'Building materials recovery,' and companies within the space are still targeting double-digit revenue growth this year, after a softer performance since late last year. Across the companies, Impack Pratama (IMPC IJ) has the highest target of +17% growth this year after growing by +26% last year. Interestingly, its margin profile is one of the highest across peers, with gross margin of 41% coming second to Avian, and third highest net margin of 16%. Asahimas Flat Glass (AMFG IJ) is another company with a similar profile, aiming at +11% revenue growth this year.



Source: CLSA, Companies

IMPC is market and price leader in roofing products

## IMPC: Leader of roofing products

IMPC is a market leader in roofing products in Indonesia, having 90% and 70% market share in its two main products of PC (polycarbonate) and uPVC roofs. With its well-known brands (Solartuff, Alderon, Alcotuff etc) and reputation since establishment in 1981, the company is also able to maintain the highest price in the market at about 20-25% higher than competitors. Other than roofing, IMPC also sells other building material products such as aluminium composite panel (ACP), pipes, vinyl flooring, uPVC ceiling and others like sealants, adhesives and plastic boards.




Source: CLSA, IMPC


Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com

# Strong roofing sales in the past three years

Across IMPC's diverse portfolio of products, roofing remains as its core business, contributing 79% of its revenue in 1Q23, followed by façade (7%), materials (3%), pipes (3%) and others (8%). Sales of roofing were strong in the past two years, increasing significantly by +31% in both 2021 and 2022, which should be partly thanks to the home renovation trend during the pandemic, and this continues in 1Q23 with +9% YoY. This enables the company's revenue to grow rapidly to Rp2.8tn in 2022 (+26% YoY), and it remain optimistic about reaching another record high this year, targeting +17% growth to Rp3.3tn.



IMPC products are widely used, growing its brand presence IMPC's products are widely used in many places such as residential, commercial areas like malls and airports (Figure 6) as well as industrial. Most of the company's products are sold through the traditional building material retail shops across Indonesia, but it also sells directly to project customers such as contractors and property developers, though the contribution is small at about 20%. Popular developers like Ciputra (CTRA IJ), Summarecon (SMRA IJ) and Agung Sedayu are among IMPC's project customers. While retail has a relatively better margin, the management is comfortable about having a good mix of project customers as it would be able to grow and expand its brand presence and at the same time able to take up larger volume orders.




3





#### Large market potential within Indonesia, especially ex-Java

IMPC's business still largely comes from the domestic Indonesia market, and the portion has been growing to 77% of sales in 1Q23 from 69% in 2020. The majority (about 90%) of this is still concentrated in Java, and the management is planning to expand its presence in areas outside Java by introducing lower-end products. Outside Indonesia, IMPC also has presence in other neighbouring countries like Malaysia, Vietnam, Australia and New Zealand, which altogether account for 23% of revenue. Management noted that it is either the first or second player in these markets.



Margin expansion from normalising raw materials cost Along with rising revenue, IMPC also managed to steadily expand its margins, mainly on the back of lower cost of raw materials. In 2021-2022, raw materials cost increased substantially, and this made the company increase its selling price by about +15% within two years (+10% in 2021 and +5% in 2022). As raw materials prices have started to normalise, IMPC is able to enjoy the expansion in margins, as reflected in 1Q23 gross margin of 41% from 35% in 2022. The company has no plans to implement another price hike this year, if raw materials prices remain stable. With this margin expansion, management is aiming net profit to reach Rp390bn (+27% YoY) this year.







Source: CLSA, IMPC

#### **AMFG: Resilient glass market**

Asahimas, the market leader in flat glass industry with 45% share, is another player in the building material space that has seen robust performance. After revenue grew by +26% and +17% in 2021 and 2022, 1Q23 revenue keeps the momentum with +7% YoY to Rp1.6tn. The auto glass segment has been especially strong following the domestic car sales trend, and has been growing faster than flat glass in recent years. This is further supported by the shift to more premium cars from LCGC (low cost green car) that uses better quality glass with higher ASP. Nevertheless, flat glass is still its main revenue contributor (70%). Sales have remained resilient and seems to be not really affected by the fuel price hike last year.





Shifting trend to smaller size houses brings higher demand for glass

Robust auto glass sales following strong domestic


car sales

Source: CLSA, AMFG

The management has observed the shifting trend towards smaller houses in the property sector, and developers are getting more creative by using more glass and mirrors in their interior design to give a more spacious feel and premium look (refer to Figure 12 as example). Management also noticed increasing use of glass components in the downstream market such as furniture and others, which also helps to support demand. With sales picking up after the pandemic, along with additional incentive from the \$6 gas price regulation from the government, margins were able to recover from the bottom in 2020 and continued to rise until 1Q23.



Source: CLSA, AMFG




5

Source: CLSA, AMFG

#### Asahimas maintaining positive outlook for this year

Asahimas's management expects the positive trend to continue this year, as it targets revenue and net profit to reach Rp6.2tn (+11% YoY) and Rp550bn (+26% YoY), respectively. However, management has anticipated several large well-known foreign players coming to Indonesia, such as KCC Glass from Korea and Xinyi Glass from China, in around 2025, which could put pressure the domestic market. Lowering debt balance is another focus of the management, with net gearing consistently declining from the peak of 123% in 2020 to 47% in 1Q23. The company's debt started back in 2016-2018 when it relocated its factory from Jakarta to Cikampek in West Java.




Source: CLSA, AMFG



#### Performance across building material players

Looking into the 1Q23 performance of building material companies that we observe, revenue generally increased in 1Q23 across the board except for ARNA as 1Q22 last year was a high base for the company due to rising demand from home renovation. It is interesting to note that AMFG's revenue is quite sizeable and is almost comparable to AVIA. In terms of earnings, IMPC has the highest net profit growth across peers at +48% YoY, ahead of its FY23 target (+17%). This is followed by SPTO (+14%) and AVIA (+8%); however, AVIA is still the largest in term of size with Rp417tn. IMPC is currently trading at 50.6x 2023 and 40.1x 2024 consensus PE, while AMFG is trading at 5.9x trailing PE.




CSAP

SPTO

(Distributor) (Sanitaryware)

#### Figure 20





Source: CLSA, IMPC, Bloomberg

#### Figure 22

Building material peers comparison														
Company	Business	Market cap (US\$bn)	P/E (x)		ROE (%)		Revenue growth			Net profit growth				
			2022	2023	2024	2022	2023	2024	2022	2023	2024	2022	2023	2024
Avia Avian (AVIA IJ)	Paint	2.7	28.7	23.3	20.9	14.8	18.2	19.2	(1%)	10%	9%	(2%)	23%	14%
Impack Pratama (IMPC IJ)	Roofing	1.3	55.8	50.6	40.1	18.9	17.9	21.2	26%	19%	19%	60%	26%	26%
Arwana (ARNA IJ)	Ceramic	0.4	12.0	n/a	n/a	37.5	28.7	29.8	1%	11%	12%	22%	5%	22%
Asahimas (AMFG IJ)	Glass	0.2	5.9	n/a	n/a	11.3	n/a	n/a	17%	n/a	n/a	37%	n/a	n/a
Catur Sentosa (CSAP IJ)	Distributor	0.2	14.1	n/a	n/a	9.8	n/a	n/a	8%	n/a	n/a	13%	n/a	n/a
Surya Pertiwi (SPTO IJ)	Sanitary	0.1	7.4	n/a	n/a	15.3	n/a	n/a	12%	n/a	n/a	5%	n/a	n/a
Average			20.7	37.0	30.5	17.9	21.6	23.4	11%	13%	13%	23%	18%	21%

Source: CLSA, Companies, Bloomberg

Prepared for - W: wirandi.ng@clsa.com





#### Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

#### **Companies mentioned**

Agung Sedayu (N-R) Arwana Citramulia (N-R) Asahimas Flat Glass (N-R) Catur (N-R) Ciputra Dev (CTRA IJ - RP1,075 - BUY) KCC Glass (N-R) Metland (N-R) PT Avia Avian Tbk (N-R) PT Impack Pratama Industri Tbk (N-R) Summarecon (SMRA IJ - RP680 - O-PF) Surya Pertiwi (N-R) Xinyi Glass (868 HK - HK\$12.44 - O-PF)

#### Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

#### Important disclosures

CLSA ("CLSA") in this report refers to CLSA Limited, CLSA Americas, LLC, CLSA Australia Pty Ltd, CLSA India Private Limited, PT CLSA Sekuritas Indonesia, CLSA Securities Japan Co., Ltd., CLSA Securities Korea Ltd., CLSA Securities Malaysia Sdn. Bhd., CLSA Philippines, Inc, CLSA Singapore Pte Ltd, CLSA Securities (Thailand) Limited, CLSA (UK), CLSA Europe B.V. and/or their respective affiliates. CLST ("CLST") in this report refers to CL Securities Taiwan Co., Ltd.

The policies of CLSA and CLST are to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out hereof and at www.clsa.com/disclaimer.html, the Conditions Terms and of Use as set out at the https://www.clsa.com/terms-and-conditions-of-use/ and applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members or associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, nonpublic information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. (For full disclosure of interest for all companies covered by CLSA in this report, please refer to http://www.clsa.com/member/research\_disclosures/ for details.)

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's and/or CLST's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF (aka ACCUMULATE): Total expected return below 20% but exceeding market return; U-PF (aka REDUCE): Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

"High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 74.67%, Underperform / SELL - CLSA: 25.33%, Restricted - CLSA: 0.00%; Data as of 1 Jul 2023. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 13.65%, Underperform / SELL - CLSA: 2.47%; Restricted - CLSA: 0.00%. Data for 12-month period ending 1 Jul 2023.

Overall rating distribution for CLST only Universe: Overall rating distribution: BUY / Outperform - CLST: 61.11%, Underperform / SELL - CLST: 38.89%, Restricted - CLST: 0.00%. Data as of 1 Jul 2023. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%, Restricted - CLST: 0.00%. Data for 12-month period ending 1 Jul 2023.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

Charts and tables sourced to CLSA in this report may include data extracted from CLSA's automated databases, which derive their original data from a range of sources. These can include: companies; analyst estimates/calculations; local exchanges and/or third-party data or market pricing providers such as Bloomberg, FactSet or IBES. Additional information on data sources for specific charts or tables can be obtained by contacting the publishing analysts.

This report is subject to and incorporates the terms and conditions use set out on the www.clsa.com website (https://www.clsa.com/disclaimer.html and https://www.clsa.com/terms -and-conditions-of use/) and the references to "publication/communication" or "Publications" thereof shall include this report. Neither this report nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this report for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data (for private or public companies) herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and CLSA and/or CLST makes no representation or warranty as to its fairness, adequacy, accuracy, completeness or correctness. The replication of any third party views in this report should not be treated necessarily as an indication that CLSA and/or CLST agrees with or concurs with such views. None of CLSA and/or CLST, its affiliates and their respective directors, officers, employees, advisers and representatives makes any representation or warranty, express or implied, as to and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such data or information contained herein or any statement made in this report. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this report and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This report is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including legal or tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to movements of exchange rate. Past performance is not necessarily a guide to future performance or liquidity. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA's Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance department nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details of conflict of interest coverage with companies under available are at http://www.clsa.com/member/research\_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company, covered in this report, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com. If you require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

Any disputes related to this report shall be governed by the laws of Hong Kong and to the non-exclusive jurisdiction of the courts of Hong Kong in connection with any suite, action or proceeding arising out of or in connection with this material. In the event any of the provisions in these Terms of Use shall be held to be unenforceable, that provision shall be enforced to the maximum extent permissible to reflect the intention underlying the unenforceable term, and the remainder of these General Disclaimer shall be unimpaired.

This report is distributed for and on behalf of CLSA (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas, LLC (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992 331/AFSL License No: 350159); in Hong Kong by CLSA Limited (Incorporated in Hong Kong with limited liability); in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor" MCI (P) 042/11/2022; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST (for reports compiled by Taiwan analyst(s) or CLSA (for non Taiwan stock reports to CLSA clients) and in the European Economic Area ('EEA") by CLSA Europe BV and in the United Kingdom by CLSA (UK).

Hong Kong: This research report is distributed by CLSA Limited. This research report is distributed in Hong Kong only to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules promulgated thereunder) and may not be distributed to retail investors. Recipients should contact CLSA Limited, Tel: +852 2600 8888 in respect of any matters arising from, or in connection with, the analysis or report.

Australia: CLSA Australia Pty Ltd ("CAPL") (ABN 53 139 992 331/AFS License No: 350159) is regulated by the Australian Securities and Investments Commission ("ASIC") and is a Market Participant of ASX Limited and Cboe Australia Pty Ltd. This material is issued and distributed by CAPL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party without the prior written consent of CAPL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. CAPL's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CAPL seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

India: CLSA India Private Limited, incorporated in November 1994 brokerage services (SEBI Registration provides equity No: . INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking services and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com. Registration granted by SEBI and certification from NISM in no way guarantee performance of CLSA India Private Limited or provide any assurance of returns to investors. Compliance officer & Grievance officer: Neeta Sanghavi, Tel: 22 6650 5050. Email address of Compliance officer and Grievance cell: compliance-india@clsa.com.

Singapore: This report is distributed in Singapore by CLSA Singapore Pte Ltd to institutional investors, accredited investors or expert investors (each as defined under the Financial Advisers Regulations) only. Singapore recipients should contact CLSA Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore 048624, Tel: +65 6416 7888, in respect of any matters arising from, or in connection with, the analysis or report. By virtue of your status as an institutional investor, accredited investor or expert investor, CLSA Singapore Pte Ltd is exempted from complying with certain requirements under the Financial Advisers Act 2001, the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder (as disclosed in Part C of the Securities Dealing Services – Singapore Annex of the CLSA terms of business), in respect of any financial advisory services that CLSA Singapore Pte Ltd may provide to you. MCI (P) 042/11/2022.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas, LLC. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA (except CLSA Americas, LLC) solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas, LLC. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas, LLC.

The United Kingdom: This document is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is disseminated in the UK by CLSA (UK) and directed at persons having professional experience in matters relating to investments, as defined in the relevant applicable local regulations. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where research material is compiled by UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules in the UK such material is authorised and regulated by the Financial Conduct Authority.

The European Economic Area ('EEA"): research is distributed by CLSA Europe BV, authorised and regulated by the Netherlands Authority for Financial Markets.

CLSA Securities Malaysia Sdn. Bhd (CLSA Malaysia)'s research coverage universe spans listed securities across the FBM KLCI Index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CLSA Malaysia seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this report may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the report in the respective jurisdictions.© 2023 CLSA and/or CL Securities Taiwan Co., Ltd. ("CLST").

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.